Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin With Berzosertib in SCLC and HGNEC
NCT04802174Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib, lurbinectedin in small cell lung cancer (SCLC), neuroendocrine cancer, solid tumor, sponsored by National Cancer Institute. Started Jun 2021; status: active, not recruiting.
02
Drugs
berzosertiblurbinectedin
03
Conditions
small cell lung cancer (SCLC)neuroendocrine cancersolid tumor
Beyond the preview
Go deeper on NCT04802174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802174.